HCV #msg-34747018 InterMune Reports Results from Triple Combination Study of ITMN-191 #msg-33270432 (AASLD Poster) HCV NS3 helicase inhibitor screening #msg-33270394 (AASLD Poster) phenotypic analysis of NS3 sequences #msg-33270382 (AASLD Poster) ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors #msg-33270355(AASLD Poster) PK-PD for ITMN-191 in a Phase 1 MAD #msg-33270341 (AASLD Poster) ITMN-191 Phase 1b #msg-33270294 (AASLD Poster) ITMN-191 Phase 1A #msg-33270262 (AASLD Poster) ITMN-5489 #msg-33446127 INFORM-1 Trial Initiation #msg-33497987 INFORM-1 Study information (from DB webcast) #msg-33967428 INFORM-1 clinical trials.gov info
IPF #msg-35288566 CAPACITY Trial Results PR #msg-34138706 Shionogi announced the launch of Pirespa (Pirfenidone) #msg-33518800 Differences between Shionogi Phase 3 and CAPACITY (Pirfenidone Phase 3) #msg-32898098 Shionogi received marketing approval